Aduro BioTech (NASDAQ:ADRO)‘s stock had its “outperform” rating reissued by research analysts at Svb Leerink in a research note issued to investors on Monday, Marketbeat reports. They currently have a $9.00 target price on the biotechnology company’s stock. Svb Leerink’s price objective indicates a potential upside of 156.41% from the company’s current price. Svb Leerink also issued estimates for Aduro BioTech’s Q2 2019 earnings at ($0.18) EPS and Q4 2019 earnings at ($0.18) EPS.
Several other analysts also recently weighed in on ADRO. Zacks Investment Research upgraded Aduro BioTech from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Wednesday, December 19th. BidaskClub downgraded Aduro BioTech from a “hold” rating to a “sell” rating in a research note on Friday, March 29th. Leerink Swann assumed coverage on Aduro BioTech in a research note on Monday. They issued an “outperform” rating on the stock. Oppenheimer restated a “buy” rating on shares of Aduro BioTech in a research note on Tuesday, March 19th. Finally, HC Wainwright restated a “buy” rating and issued a $8.30 price target on shares of Aduro BioTech in a research note on Wednesday, December 19th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $7.68.
ADRO stock opened at $3.51 on Monday. Aduro BioTech has a fifty-two week low of $2.34 and a fifty-two week high of $9.00. The company has a market cap of $293.06 million, a price-to-earnings ratio of -3.03 and a beta of 2.06.
Aduro BioTech (NASDAQ:ADRO) last posted its earnings results on Wednesday, February 27th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.10). Aduro BioTech had a negative return on equity of 54.84% and a negative net margin of 632.05%. As a group, sell-side analysts expect that Aduro BioTech will post -0.78 earnings per share for the current fiscal year.
In other news, insider Elsas Andrea Van sold 6,844 shares of the stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $4.25, for a total transaction of $29,087.00. Following the transaction, the insider now directly owns 245,638 shares of the company’s stock, valued at approximately $1,043,961.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jennifer Lew sold 18,601 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $4.07, for a total value of $75,706.07. Following the completion of the transaction, the chief financial officer now directly owns 139,380 shares in the company, valued at $567,276.60. The disclosure for this sale can be found here. Insiders sold a total of 31,526 shares of company stock worth $128,874 over the last ninety days. 5.20% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in ADRO. Geode Capital Management LLC increased its stake in Aduro BioTech by 11.3% in the 4th quarter. Geode Capital Management LLC now owns 627,397 shares of the biotechnology company’s stock worth $1,656,000 after buying an additional 63,447 shares in the last quarter. Norges Bank purchased a new stake in Aduro BioTech in the 4th quarter worth $370,000. Dimensional Fund Advisors LP increased its stake in Aduro BioTech by 90.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 560,660 shares of the biotechnology company’s stock worth $1,480,000 after buying an additional 266,372 shares in the last quarter. Millennium Management LLC increased its stake in Aduro BioTech by 25.0% in the 4th quarter. Millennium Management LLC now owns 116,376 shares of the biotechnology company’s stock worth $307,000 after buying an additional 23,310 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in Aduro BioTech by 25.6% in the 4th quarter. Legal & General Group Plc now owns 30,303 shares of the biotechnology company’s stock worth $80,000 after buying an additional 6,184 shares in the last quarter. 44.82% of the stock is currently owned by institutional investors.
Aduro BioTech Company Profile
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Read More: Dividend
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.